Preliminary Scientific Program - ICHIC April 8-10, 2016

Friday April 8th 2016

9,00 - 11,00 am  Industry sponsored session

11,00 - 11,15 am  Congress Opening: A Falanga, FR Rickles, B Brenner

11,15 - 1,30 pm  Plenary Session 1: Epidemiology of thrombosis in cancer
    Chairs: N Key (USA); TBA
    - Venous thromboembolism and occult cancer: impact on clinical practice
      M Carrier (Canada)
    - Cancer associated thrombosis: risk factors and outcomes
      S Eichingher (Austria)
    - Update of incidental VTE in cancer
      H Liebman (USA)
    - Thrombosis and anticancer therapies: the contribution of chemotherapy and the specific drugs implicated in CAT
      P Mismetti (France)

Oral Communications
2,30 - 4,45 pm

**Plenary Session 2: Role of hemostatic pathways in cancer progression**

*Chairs: TBA*

- **Microparticles and cancer thrombosis in animal models**  
  C Dubois (France)

- **Inhibition of platelet function as a target for cancer progression control**  
  J Italiano (USA)

- **Biological basis of personalised anticoagulation in cancer: oncomir networks as regulators of coagulopathy**  
  J Rak (Canada)

- **Heparanase procoagulant activity in cancer progression**  
  Y Nadir (Israel)

**Oral Communications**
5,15 - 7,30 pm  **Plenary Session 3: Old and emerging biomarkers for thrombosis and disease progression in cancer**  
*Chairs: B Brenner (Israel); S Kostantinides (Germany)*  

- **Cancer-associated thrombosis novel biomarker discovery**  
  *N Kuderer (USA)*  

- **VTE risk assessment models in cancer**  
  *I Pabinger (Austria)*  

- **Polymorphisms of clotting factors and cancer risk**  
  *P Sandset (Sweeden)*  

- **The HYPERCAN prospective study**  
  *A Falanga (Italy)*

**Oral Communications**

7,30 pm  **Plenary Lecture: 4th Simon Karpatkin Memorial Lecture**  
*Chairs: A Falanga (Italy); B Brenner (Israel); FR Rickles (USA)*

**Introduction to Lecture**  
*FR Rickles (USA)*

**Targeting clotting proteins in cancer therapy - progress and challenges**  
*W Ruf (USA, Germany)*
Saturday April 9th 2016

8,30 - 10,45 am  **Plenary Session 4: Hematological malignancies and hemostatic complications**  
*Chairs: TBA*

- Intracranial hemorrhage in cancer patients on anticoagulation  
  *J Zwicker (USA)*
- Management of cancer-associated disseminated intravascular coagulation  
  *M Levi (The Netherlands)*
- New insights into the biology and management of thrombosis in myeloproliferative neoplasms  
  *T Barbui (Italy)*
- Update of thrombosis in multiple myeloma  
  *FWG Leebeek (The Netherlands)*

**Oral Communications**
11,15 am - 1,30 pm  **Plenary Session 5: Risk factors for thrombosis in cancer**  
*Chairs: I Elalamy (France); GM Liumbruno (Italy)*

- Upper extremity deep vein thrombosis: comparison between cancer and non-cancer patients  
  *SM Bleker (The Netherlands)*
- Risk of thrombosis and supportive care (transfusion, catheters, growth factors)  
  *TBA*
- New findings from global registries of cancer-associated thrombosis  
  *AK Kakkar (UK)*
- Predictors of recurrent VTE and bleeding on anticoagulation  
  *AA Khorana (USA)*

Oral Communications

2,30 - 3,00 pm  **Special Session: History of ICTHIC**  
*Chair: H Liebman (USA); A Falanga (Italy); B Brenner (Israel)*

**History of ICTHIC - How has the field progressed since our first meeting in 2001?**  
*F Rickles (USA)*

3,00 - 5,00 pm  **Poster sessions with refreshments**  
*Poster walk discussion sessions with chair*
4,30 - 6,45 pm  

**Plenary Session 6: Prophylaxis of thrombosis in cancer patients**

*Chairs: TBA*

Thromboprophylaxis in hospitalized Cancer Patients: a comparison of guidelines  
*M. Levine (USA)*

Long term cardiovascular complications of chemotherapy in patients with cancer  
*P. W. Kamphuisen (The Netherlands)*

DOACs in cancer patients - what is known and what are the active trials  
*G Agnelli (Italy)*

**Oral Communications**
Sunday April 10th 2016

8,30 - 10,45 am  **Plenary Session 7: Treatment of cancer-associated thrombosis**
Chairs: H ten Cate (The Netherlands); G Lyman (USA)

- CAT treatment: guidelines update
  AYY Lee (Canada)
- Management of recurrent venous thromboembolism in cancer patients
  W Ageno (Italy)
- The use of vena cava filter in patients with cancer
  T Wun (USA)
- Management of bleeding complications in cancer patients on DOACs
  S Schulman (Canada)

**Oral Communications**
11.15 am - 1,30 pm  **Plenary session 8: Open questions in cancer and thrombosis**
Chairs: H Buller (Germany)

- **Anticoagulant and cancer: Will overall survival increase?**
  HH Veersteg (The Netherlands)
- **Does one size fit all? Who should get LMWH/warfarin/DOACs?**
  S Noble (UK)
- **LMWH in cancer patients with renal impairment - better than warfarin?**
  R Bauersachs (Germany)
- **Laboratory determination of old and new targeted anticoagulant agents for prevention of bleeding and thrombotic events in cancer patients**
  J Harenberg (Germany)

**Oral Communications**

1,30 - 1,45 pm  **Concluding Remarks**